KZR vs. NXTC, HOOK, PRLD, OMER, ZVRA, PBYI, IVA, IXHL, LFCR, and OGI
Should you be buying Kezar Life Sciences stock or one of its competitors? The main competitors of Kezar Life Sciences include NextCure (NXTC), Hookipa Pharma (HOOK), Prelude Therapeutics (PRLD), Omeros (OMER), Zevra Therapeutics (ZVRA), Puma Biotechnology (PBYI), Inventiva (IVA), Incannex Healthcare (IXHL), Lifecore Biomedical (LFCR), and Organigram (OGI). These companies are all part of the "pharmaceutical preparations" industry.
Kezar Life Sciences (NASDAQ:KZR) and NextCure (NASDAQ:NXTC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation, community ranking and profitability.
Kezar Life Sciences' return on equity of -47.28% beat NextCure's return on equity.
Kezar Life Sciences has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500. Comparatively, NextCure has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500.
In the previous week, NextCure had 4 more articles in the media than Kezar Life Sciences. MarketBeat recorded 6 mentions for NextCure and 2 mentions for Kezar Life Sciences. Kezar Life Sciences' average media sentiment score of 1.25 beat NextCure's score of 0.79 indicating that Kezar Life Sciences is being referred to more favorably in the media.
67.9% of Kezar Life Sciences shares are owned by institutional investors. Comparatively, 42.7% of NextCure shares are owned by institutional investors. 9.3% of Kezar Life Sciences shares are owned by insiders. Comparatively, 13.3% of NextCure shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Kezar Life Sciences received 56 more outperform votes than NextCure when rated by MarketBeat users. However, 63.93% of users gave NextCure an outperform vote while only 58.01% of users gave Kezar Life Sciences an outperform vote.
NextCure has lower revenue, but higher earnings than Kezar Life Sciences. NextCure is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks.
Kezar Life Sciences presently has a consensus price target of $11.00, suggesting a potential upside of 1,485.01%. NextCure has a consensus price target of $6.00, suggesting a potential upside of 289.61%. Given Kezar Life Sciences' higher possible upside, equities research analysts plainly believe Kezar Life Sciences is more favorable than NextCure.
Summary
Kezar Life Sciences beats NextCure on 9 of the 16 factors compared between the two stocks.
Get Kezar Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for KZR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KZR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kezar Life Sciences Competitors List
Related Companies and Tools
